Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

Arbor. "As a specialty pharmaceutical company already focused in the cardiovascular area, we are well-positioned to ensure the EDARBI products are available to all appropriate patients who may need them."

About Hypertension
Hypertension, or high blood pressure, is a chronic medical condition in which blood pressure is elevated to levels of 140 mm Hg or greater systolic and/or 90 mm Hg or greater diastolic. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of blood pressure in individuals with severe hypertension can provide substantial benefit.

Hypertension impacts approximately 67 million Americans, or nearly one in three adults. It is estimated that nearly one billion people are affected by hypertension worldwide, and this figure is predicted to increase to 1.5 billion by 2025. Hypertension typically has no symptoms. Adults of all ages and backgrounds can develop hypertension; however, the risk of developing the condition increases with age, with more than half of people over age 60 affected. Hypertension is also costly to the nation's health care system. The American Heart Association recently estimated that direct and indirect expenses associated with hypertension cost the nation more than $73 billion in 2009.

About EDARBI and EDARBYCLOR
EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) developed by Takeda for the treatment of hypertension to lower blood pressure in adults. EDARBI lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone, which naturally exists within the body. When EDARBI blocks the angiotensin II receptor, blood vessels can stay relaxed and open, and blood pressure can be reduced. EDARBI is indicated for the treatment of hypertension to lower blood pressure in adults, either alone or in combination with other antihypertensive
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... NEWTON, Mass. , Aug. 5 Microfluidics International Corporation (OTC Bulletin Board: ... on Tuesday, August 10, 2010 , at 8:30am ET . , ... (Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO ) , , ... ) , , , ...
... 5 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that its product candidate CRTX-067 is an ... mg hydrocodone polistirex suspension product that will be a ...
Cached Medicine Technology:Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 2Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 3Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 4Cornerstone Therapeutics Announces Development of Generic for Tussionex® 2Cornerstone Therapeutics Announces Development of Generic for Tussionex® 3
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... American Diabetes Association , ... Welch, Minn. (Vocus) May ... the serious health issues that are associated with diabetes. Type 2 ... those who are 19 years and older. Diabetes has reached epidemic ...
... job loss has impacted most people in every socio-economic ... stimulus combo-packages on BOTOX® Cosmetic and fillers, like Restylane ... feel at the top of their game, improve self ... market and erase unwanted worry lines and reflections of ...
... a Series of Community Discussions on Improving Access to ... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today ... as part of their Year of Affordable Healthcare campaign ... the YMCA San Francisco, aimed at raising awareness of ...
... Directed Verdict that Rescission was ProperSAN FRANCISCO, May 28 ... General Counsel Seth Jacobs:Today,s verdict is a complete vindication for ... every step of the way. It means that our ... and we acted in good faith. There was no ...
... Inc. (NYSE: DVA ) announced today ... the Company,s Board of Directors. (Logo: ... former President of American Express International, Japan, Asia-Pacific, ... the Consumer Card business across 12 countries, heading ...
... May 28 The London Fire Department has ... breathing apparatus and monitoring systems. Representing a ... largest firefighting service, the order also reflects a ... work closely together to ensure even greater protection ...
Cached Medicine News:Health News:Prairie Island Indian Community Supports Fight Against Diabetes Locally and Nationally 2Health News:Infini Cosmetic Associates Offers Boomer Stimulus Packages to Offset Aging and Help Job Seekers Get a Fresh Start 2Health News:Infini Cosmetic Associates Offers Boomer Stimulus Packages to Offset Aging and Help Job Seekers Get a Fresh Start 3Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:Pamela M. Arway Joins DaVita Board of Directors 2Health News:London, England Fire Department Places Major Order with Draeger 2
As with all Eschmann products the T20 operating table was designed with 'Simplicity and Intuitiveness' in mind, having drawn influences from leading clinicians of various levels from across the globe...
... carbon fiber c-arm table allows 50 ... brachytherapy, gynecology, gastroenterology, cardiovascular, orthopedic, ENT, ... design allows easy access for all ... 16-inch elevating travel, 16-inch longitudinal travel, ...
... imaging table is a fully digital imaging ... and advanced patient data management system. The ... the industry providing unsurpassed access for both ... to either a right- or left- hand ...
... Designed for procedures where stability, ... are essential. A cantilevered low attenuation ... ceiling-suspended C-Arms. The radiolucent area is ... fluoroscopic visualization and unobstructed C-Arm positioning. ...
Medicine Products: